FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF
Provided is a fusion protein dimer comprising a protein which specifically binds to the extracellular domain of CRIg or a fragment thereof and VEGF. The protein may inhibit complement-related pathways and also may efficiently regulate angiogenesis. Thus, the fusion protein dimer can be effectively a...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; kor |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Provided is a fusion protein dimer comprising a protein which specifically binds to the extracellular domain of CRIg or a fragment thereof and VEGF. The protein may inhibit complement-related pathways and also may efficiently regulate angiogenesis. Thus, the fusion protein dimer can be effectively applied to the treatment and prevention of complement-related diseases, in particular, eye diseases such as macular degeneration, and thus, has high industrial applicability.
L'invention concerne un dimère de protéine de fusion comprenant une protéine qui se lie spécifiquement au domaine extracellulaire de CRIg ou d'un fragment de celui-ci et à VEGF. La protéine peut inhiber les voies liées au complément et peut également réguler efficacement l'angiogenèse. Ainsi, le dimère de protéine de fusion peut être efficacement appliqué au traitement et à la prévention de maladies liées au complément, en particulier, des maladies oculaires comme la dégénérescence maculaire, et présente ainsi une applicabilité industrielle élevée.
CRIg의 세포외도메인 또는 이의 단편 및 VEGF에 특이적으로 결합하는 단백질을 포함하는 융합단백질 이량체를 제공한다. 상기 단백질은 보체 관련 경로를 억제할 뿐 아니라 신생혈관생성을 효율적으로 조절할 수 있다. 따라서, 상기 융합단백질 이량체는 보체 관련 질환, 구체적으로 황반 변성과 같은 안질환의 치료 및 예방에 효과적으로 활용할 수 있어 산업적 활용 가능성이 높다. |
---|